Regulation of ASPP2 Interaction with p53 Core Domain by an Intramolecular Autoinhibitory Mechanism

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Rotem Bamberger, Shahar ^a   Katz, Chen ^a   Friedler, Assaf ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN ASPP2; PROTEIN BCL 2; PROTEIN P53; PROTEIN SH3; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; PEPTIDE; PROLINE; TP53 PROTEIN, HUMAN; TP53BP2 PROTEIN, HUMAN;

AMINO ACID SEQUENCE; ANISOTROPY; ARTICLE; BINDING COMPETITION; BINDING SITE; BIOPHYSICS; COMPLEX FORMATION; EMISSION ANISOTROPY; INTRAMOLECULAR AUTOINHIBITORY MECHANISM; MOLECULAR DOCKING; MOLECULAR INTERACTION; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; CHEMICAL STRUCTURE; FLUORESCENCE MICROSCOPY; FLUORESCENCE POLARIZATION; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; PROTEIN TERTIARY STRUCTURE; SRC HOMOLOGY DOMAIN;

APOPTOSIS REGULATORY PROTEINS; BINDING SITES; FLUORESCENCE POLARIZATION; GENE EXPRESSION REGULATION; HUMANS; MICROSCOPY, FLUORESCENCE; MODELS, MOLECULAR; NF-KAPPA B; PEPTIDES; PROLINE; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-BCL-2; SRC HOMOLOGY DOMAINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84874620340     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058470     Document Type: Article

References (39)

1. Suzuki K, Matsubara H, (2011) Recent advances in p53 research and cancer treatment. J Biomed Biotechnol 2011: 978312.
2. Vousden KH, Prives C, (2009) Blinded by the Light: The Growing Complexity of p53. Cell 137: 413-431.
3. Vogelstein B, Lane D, Levine AJ, (2000) Surfing the p53 network. Nature 408: 307-310.
4. Ryan KM, Phillips AC, Vousden KH, (2001) Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol 13: 332-337.
5. Michael D, Oren M, (2002) The p53 and Mdm2 families in cancer. Curr Opin Genet Dev 12: 53-59.
6. Joerger AC, Fersht AR, (2007) Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene 26: 2226-2242.
7. Bergamaschi D, Samuels Y, O'Neil NJ, Trigiante G, Crook T, et al. (2003) iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet 33: 162-167.
8. Samuels-Lev Y, O'Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, et al. (2001) ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 8: 781-794.
9. Liu WK, Jiang XY, Ren JK, Zhang ZX, (2010) Expression pattern of the ASPP family members in endometrial endometrioid adenocarcinoma. Onkologie 33: 500-503.
10. Zhao J, Wu G, Bu F, Lu B, Liang A, et al. (2010) Epigenetic silence of ankyrin-repeat-containing, SH3-domain-containing, and proline-rich-region- containing protein 1 (ASPP1) and ASPP2 genes promotes tumor growth in hepatitis B virus-positive hepatocellular carcinoma. Hepatology 51: 142-153.
11. Naumovski L, Cleary ML, (1996) The p53-binding protein 53BP2 also interacts with Bc12 and impedes cell cycle progression at G2/M. Mol Cell Biol 16: 3884-3892.
12. Tidow H, Andreeva A, Rutherford TJ, Fersht AR, (2007) Solution structure of ASPP2 N-terminal domain (N-ASPP2) reveals a ubiquitin-like fold. J Mol Biol 371: 948-958.
13. Rotem S, Katz C, Benyamini H, Lebendiker M, Veprintsev D, et al. (2008) The structure and interactions of the proline-rich domain of ASPP2. J Biol Chem 283: 18990-18999.
14. Gorina S, Pavletich NP, (1996) Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science 274: 1001-1005.
15. Robinson RA, Lu X, Jones EY, Siebold C, (2008) Biochemical and structural studies of ASPP proteins reveal differential binding to p53, p63, and p73. Structure 16: 259-268.
16. Kampa KM, Bonin M, Lopez CD, (2009) New insights into the expanding complexity of the tumor suppressor ASPP2. Cell Cycle 8: 2871-2876.
17. Yang JP, Hori M, Takahashi N, Kawabe T, Kato H, et al. (1999) NF-kappaB subunit p65 binds to 53BP2 and inhibits cell death induced by 53BP2. Oncogene 18: 5177-5186.
18. Perkins ND, Gilmore TD, (2006) Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ 13: 759-772.
19. Ryan KM, Ernst MK, Rice NR, Vousden KH, (2000) Role of NF-kappaB in p53-mediated programmed cell death. Nature 404: 892-897.
20. Adams JM, Cory S, (2007) The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26: 1324-1337.
21. Benyamini H, Leonov H, Rotem S, Katz C, Arkin IT, et al. (2009) A model for the interaction between NF-kappa-B and ASPP2 suggests an I-kappa-B-like binding mechanism. Proteins 77: 602-611.
22. Katz C, Benyamini H, Rotem S, Lebendiker M, Danieli T, et al. (2008) Molecular basis of the interaction between the antiapoptotic Bcl-2 family proteins and the proapoptotic protein ASPP2. Proc Natl Acad Sci U S A 105: 12277-12282.
23. Espanel X, Sudol M, (2001) Yes-associated protein and p53-binding protein-2 interact through their WW and SH3 domains. J Biol Chem 276: 14514-14523.
24. Bouchet BP, de Fromentel CC, Puisieux A, Galmarini CM, (2006) p53 as a target for anti-cancer drug development. Crit Rev Oncol Hematol 58: 190-207.
25. Cho Y, Gorina S, Jeffrey PD, Pavletich NP, (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346-355.
26. Bullock AN, Henckel J, DeDecker BS, Johnson CM, Nikolova PV, et al. (1997) Thermodynamic stability of wild-type and mutant p53 core domain. Proc Natl Acad Sci U S A 94: 14338-14342.
27. Friedler A, Hansson LO, Veprintsev DB, Freund SM, Rippin TM, et al. (2002) A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci U S A 99: 937-942.
28. Friedler A, DeDecker BS, Freund SM, Blair C, Rudiger S, et al. (2004) Structural distortion of p53 by the mutation R249S and its rescue by a designed peptide: implications for "mutant conformation". J Mol Biol 336: 187-196.
29. Issaeva N, Friedler A, Bozko P, Wiman KG, Fersht AR, et al. (2003) Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc Natl Acad Sci U S A 100: 13303-13307.
30. Hayouka Z, Rosenbluh J, Levin A, Loya S, Lebendiker M, et al. (2007) Inhibiting HIV-1 integrase by shifting its oligomerization equilibrium. Proc Natl Acad Sci U S A 104: 8316-8321.
31. Benyamini H, Friedler A, (2011) The ASPP interaction network: electrostatic differentiation between pro- and anti-apoptotic proteins. J Mol Recognit 24: 266-274.
32. Tidow H, Veprintsev DB, Freund SM, Fersht AR, (2006) Effects of oncogenic mutations and DNA response elements on the binding of p53 to p53-binding protein 2 (53BP2). J Biol Chem 281: 32526-32533.
33. Prilusky J, Felder CE, Zeev-Ben-Mordehai T, Rydberg EH, Man O, et al. (2005) FoldIndex: a simple tool to predict whether a given protein sequence is intrinsically unfolded. Bioinformatics 21: 3435-3438.
34. Linding R, Russell RB, Neduva V, Gibson TJ, (2003) GlobPlot: Exploring protein sequences for globularity and disorder. Nucleic Acids Res 31: 3701-3708.
35. Yang ZR, Thomson R, McNeil P, Esnouf RM, (2005) RONN: the bio-basis function neural network technique applied to the detection of natively disordered regions in proteins. Bioinformatics 21: 3369-3376.
36. Kay BK, Williamson MP, Sudol M, (2000) The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains. FASEB J 14: 231-241.
37. Saksela K, Permi P, (2012) SH3 domain ligand binding: What's the consensus and where's the specificity? FEBS Lett.
38. Takahashi N, Kobayashi S, Kajino S, Imai K, Tomoda K, et al. (2005) Inhibition of the 53BP2S-mediated apoptosis by nuclear factor kappaB and Bcl-2 family proteins. Genes Cells 10: 803-811.
39. Rotem S, Katz C, Friedler A, (2007) Insights into the structure and protein-protein interactions of the pro-apoptotic protein ASPP2. Biochem Soc Trans 35: 966-969.